Cargando…

C‐C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment

Chemokines and their receptors have key roles in cancer progression. The present study investigated chemokine activity in the prostate cancer bone metastasis microenvironment. Growth and migration of human prostate cancer cells were assayed in cocultures with bone stromal cells. The migration of LNC...

Descripción completa

Detalles Bibliográficos
Autores principales: Urata, Satoko, Izumi, Kouji, Hiratsuka, Kaoru, Maolake, Aerken, Natsagdorj, Ariunbold, Shigehara, Kazuyoshi, Iwamoto, Hiroaki, Kadomoto, Suguru, Makino, Tomoyuki, Naito, Renato, Kadono, Yoshifumi, Lin, Wen‐Jye, Wufuer, Guzailinuer, Narimoto, Kazutaka, Mizokami, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834783/
https://www.ncbi.nlm.nih.gov/pubmed/29288523
http://dx.doi.org/10.1111/cas.13494
Descripción
Sumario:Chemokines and their receptors have key roles in cancer progression. The present study investigated chemokine activity in the prostate cancer bone metastasis microenvironment. Growth and migration of human prostate cancer cells were assayed in cocultures with bone stromal cells. The migration of LNCaP cells significantly increased when co‐cultured with bone stromal cells isolated from prostate cancer bone metastases. Cytokine array analysis of conditioned medium from bone stromal cell cultures identified CCL5 as a concentration‐dependent promoter of LNCaP cell migration. The migration of LNCaP cells was suppressed when C‐C motif ligand 5 (CCL5) neutralizing antibody was added to cocultures with bone stromal cells. Knockdown of androgen receptor with small interfering RNA increased the migration of LNCaP cells compared with control cells, and CCL5 did not promote the migration of androgen receptor knockdown LNCaP. Elevated CCL5 secretion in bone stromal cells from metastatic lesions induced prostate cancer cell migration by a mechanism consistent with CCL5 activity upstream of androgen receptor signaling.